Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | KIT |
Variant | T417_D419delinsI |
Impact List | indel |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | KIT T417_D419delinsI results in the deletion of three amino acids in Ig-like C2-type domain 5 of the Kit protein from amino acids 417 to 419, combined with the insertion of an isoleucine (I) at the same site (UniProt.org). T417_D419delinsI results in constitutive ligand-independent phosphorylation of Kit in cell culture (PMID: 16015387), and therefore, is predicted to lead to a gain of Kit protein function. |
Associated Drug Resistance | |
Category Variants Paths |
KIT mutant KIT act mut KIT T417_D419delinsI KIT mutant KIT exon8 KIT T417_D419delinsI |
Transcript | NM_000222.3 |
gDNA | chr4:g.54723601_54723609delinsATC |
cDNA | c.1249_1257delinsATC |
Protein | p.T417_D419delinsI |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_000222.3 | chr4:g.54723601_54723609delinsATC | c.1249_1257delinsATC | p.T417_D419delinsI | RefSeq | GRCh38/hg38 |
NM_001385285.1 | chr4:g.54723601_54723609delinsATC | c.1249_1257delinsATC | p.T417_D419delinsI | RefSeq | GRCh38/hg38 |
NM_000222.2 | chr4:g.54723601_54723609delinsATC | c.1249_1257delinsATC | p.T417_D419delinsI | RefSeq | GRCh38/hg38 |
NM_000222 | chr4:g.54723601_54723609delinsATC | c.1249_1257delinsATC | p.T417_D419delinsI | RefSeq | GRCh38/hg38 |
XM_017008178 | chr4:g.54723601_54723609delinsATC | c.1249_1257delinsATC | p.T417_D419delinsI | RefSeq | GRCh38/hg38 |
XM_017008180.1 | chr4:g.54723601_54723609delinsATC | c.1249_1257delinsATC | p.T417_D419delinsI | RefSeq | GRCh38/hg38 |
NM_001093772.2 | chr4:g.54723601_54723609delinsATC | c.1249_1257delinsATC | p.T417_D419delinsI | RefSeq | GRCh38/hg38 |
NM_001093772.1 | chr4:g.54723601_54723609delinsATC | c.1249_1257delinsATC | p.T417_D419delinsI | RefSeq | GRCh38/hg38 |
XM_017008178.1 | chr4:g.54723601_54723609delinsATC | c.1249_1257delinsATC | p.T417_D419delinsI | RefSeq | GRCh38/hg38 |
NM_001093772 | chr4:g.54723601_54723609delinsATC | c.1249_1257delinsATC | p.T417_D419delinsI | RefSeq | GRCh38/hg38 |
NM_001385286.1 | chr4:g.54723601_54723609delinsATC | c.1249_1257delinsATC | p.T417_D419delinsI | RefSeq | GRCh38/hg38 |
XM_017008180 | chr4:g.54723601_54723609delinsATC | c.1249_1257delinsATC | p.T417_D419delinsI | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT T417_D419delinsI | Advanced Solid Tumor | conflicting | Imatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation in transformed cells over expressing KIT T417_D419delinsI in culture (PMID: 16015387). | 16015387 |
KIT T417_D419delinsI | Advanced Solid Tumor | conflicting | Imatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing KIT T417_D419delinsI were resistant to treatment with Gleevec (imatinib) in culture (PMID: 24205792). | 24205792 |
KIT T417_D419delinsI | Advanced Solid Tumor | sensitive | Flumatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing KIT T417_D419delinsI were sensitive to treatment with Flumatinib, demonstrating decreased cell proliferation (PMID: 24205792). | 24205792 |
KIT T417_D419delinsI | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing KIT T417_D419delinsI were sensitive to treatment with Sutent (sunitinib), demonstrating decreased cell proliferation (PMID: 24205792). | 24205792 |